Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · CITIUS ONCOLOGY, INC. (CTOR)

Citius Oncology reports quality of life data for LYMPHIR in relapsed CTCL trial

Neutral Impact 2 of 5 other Written later

Citius Oncology announced health-related quality of life results from pivotal Study 302 of LYMPHIR, presented at the EORTC-CLTG 2026 Annual Meeting in Berlin. The company reported sustained quality of life improvements among responders, but the analyses were descriptive, the study was not designed or powered for these outcomes, and the results are not included in the LYMPHIR Prescribing Information. The filing contains no revenue, earnings, or guidance figures, so it provides clinical data without a stated financial effect on shareholders.

Key points

  • Study 302 data were presented October 8-10, 2026, at the EORTC-CLTG 2026 Annual Meeting in Berlin; the press release is dated November 4, 2026.
  • Among responders (n=25) in the primary analysis set (n=69), mean change in Skindex-29 Total Score ranged from -5.38 to -13.69 points, where lower scores indicate better quality of life.
  • Among 41 heavily pretreated patients with baseline itch of 20 mm or greater, 13 (32%) achieved a clinically meaningful improvement.
  • No formal statistical comparisons were performed, and the results are not included in the LYMPHIR Prescribing Information.

The filing

CompanyCITIUS ONCOLOGY, INC. (CTOR)
Form8-K, current report
Filed with the SECNov 4, 2026, 4:30 PM ET
Accession number0001213900-26-115964

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.